Brief discussion on research progress in Nipah virus and Nipah virus vaccines
10.3760/cma.j.cn112309-20231222-00187
- VernacularTitle:浅谈尼帕病毒及尼帕病毒疫苗研究进展
- Author:
Hongshan XU
1
;
Xinyu LIU
;
Lihong YANG
;
Guangzhi YUE
;
Qiang YE
;
Yuhua LI
Author Information
1. 中国食品药品检定研究院虫媒病毒疫苗室，北京 102629
- Keywords:
Nipah virus;
Prevention and control;
Henipavirus;
Zoonosis;
Nipah virus vaccine
- From:
Chinese Journal of Microbiology and Immunology
2024;44(11):970-977
- CountryChina
- Language:Chinese
-
Abstract:
Nipah virus (NiV) is a highly contagious zoonotic pathogen, responsible for a relatively high mortality in human and posing a serious threat to human health. There are currently no licensed vaccines or antiviral drugs. Preclinical studies on NiV vaccines with different strategies are mainly based on NiV glycoprotein (G) and/or fusion protein (F). Internationally, three NiV vaccine candidates are currently in the Phase I clinical stage. The risk of Nipah virus transmitted to China is relatively high. In order to cope with potential future epidemics, China should develop NiV prevention and control strategies, and accelerate Nipah virus-related technology reserves and vaccine development. This article introduces NiV from the aspects of microbiology, epidemiology, clinical characteristics, and vaccine research, and puts forward prevention and control suggestions in light of the risk of NiV transmission to China and China′s national conditions, hoping to provide reference for NiV vaccine research and development.
